Pneumocystis jirovecii pneumonia in non-HIV patients: need for a more extended prophylaxis.

ABSTRACT:

Background

Pneumocystis jirovecii pneumonia (PCP) has a significant mortality rate for non-HIV immunocompromised patients. Prevention is primarily based on combined trimethoprim and sulfamethoxazole (TMP-SMX) but guidelines on pneumocystosis prophylaxis are scattered and not consensual.

Objectives

This study aims to describe PCP in non-HIV patients and to review case by case the prior indication of prophylaxis according to specific guidelines.We included patients with confirmed diagnosis of PCP admitted to one university hospital from 2007 to 2020. Prior indication for pneumocystis prophylaxis was assessed according to the specific guidelines for the underlying pathology or treatment.

Results

Of 150 patients with a medical diagnosis of PCP, 78 were included. Fo

SUBMITTER: Sauvat L 

PROVIDER: S-EPMC11233525 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature